---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-043821"
form_type: "8-K"
ticker: "PCSA"
cik: "0001533743"
company_name: "Processa Pharmaceuticals, Inc."
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:30:55.729190+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Processa Pharmaceuticals replaces auditor BD & Co. with Cherry Bekaert

## Summary
- BD & Co. resigned Oct 31, 2024 after merger into Citrin Cooperman; no disagreements or reportable events.
- Audit Committee appointed Cherry Bekaert LLP for FY 2024 and subsequent interim periods.
- No prior consultations with Cherry Bekaert regarding accounting principles or disagreements.
- BD & Co.'s audit reports for 2023 and 2022 were unqualified and contained no adverse opinion.

## SEC filing metadata
- accession: 0001493152-24-043821
- form_type: 8-K
- ticker: PCSA
- cik: 0001533743
- company_name: Processa Pharmaceuticals, Inc.
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 4.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533743/000149315224043821/0001493152-24-043821-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533743/000149315224043821/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-043821
- JSON: https://secwatch.observer/filing/0001493152-24-043821.json
- Plain text: https://secwatch.observer/filing/0001493152-24-043821.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.